Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.

Leiter LA, Lundman P, da Silva PM, Drexel H, Jünger C, Gitt AK; DYSIS investigators.

Diabet Med. 2011 Nov;28(11):1343-51. doi: 10.1111/j.1464-5491.2011.03360.x.

PMID:
21679231
2.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
3.

Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.

Stalenhoef AF, Davidson MH, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H.

Diabetes Obes Metab. 2012 Jan;14(1):30-9. doi: 10.1111/j.1463-1326.2011.01485.x. Epub 2011 Nov 21.

PMID:
21819519
4.
5.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

6.

Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.

Sampalis JS, Bissonnette S, Habib R, Boukas S; Ezetrol Add-On Investigators.

Ann Pharmacother. 2007 Sep;41(9):1345-51. Epub 2007 Jul 31.

PMID:
17666579
7.

Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.

Gupta M, Szmitko PE, Tsigoulis M, Braga MF, Kajil M, Herjikaka S, Quan A, Teoh H, Verma S.

J Cardiovasc Pharmacol. 2010 Sep;56(3):241-5. doi: 10.1097/FJC.0b013e3181e7fd74.

PMID:
20505518
8.

How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.

Leiter LA, Martineau P, de Teresa E, Farsang C, Gaw A, Gensini G, Langer A; ACTFAST 1 & 2 investigators.

J Fam Pract. 2008 Oct;57(10):661-8.

PMID:
18842192
9.

The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.

Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.

Curr Med Res Opin. 2008 Mar;24(3):685-94. doi: 10.1185/030079908X273273. Epub 2008 Jan 25.

PMID:
18226326
10.

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.

Jones PH.

Am J Cardiol. 2008 Dec 22;102(12A):41L-47L. doi: 10.1016/j.amjcard.2008.09.074. Review.

PMID:
19084089
11.
12.

A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.

Davidson M.

Am J Cardiol. 2008 Dec 22;102(12A):19L-27L. doi: 10.1016/j.amjcard.2008.09.071. Review.

PMID:
19084086
13.

Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).

da Silva PM, Cardoso SM; Investigadores do Estudo DYSIS Portugal.

Rev Port Cardiol. 2011 Jan;30(1):47-63. English, Portuguese.

PMID:
21425743
14.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
15.

[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].

Brath H, Wascher TC, Kästenbauer T, Toplak H.

MMW Fortschr Med. 2012 Jun 28;154 Suppl 2:41-7. German.

PMID:
23424754
16.

[Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].

Pérez A, González Blanco C, Hernández-Presa MÁ, Chaves J.

Endocrinol Nutr. 2011 Jun-Jul;58(6):283-90. doi: 10.1016/j.endonu.2011.03.005. Spanish.

PMID:
21641286
17.

Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.

Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D.

Curr Med Res Opin. 2005 Sep;21(9):1389-99.

PMID:
16197657
18.

Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.

Bruckert E, Baccara-Dinet M, Eschwege E.

Diabet Med. 2007 Apr;24(4):388-91. Epub 2007 Feb 28.

PMID:
17335463
19.

Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS).

Marques da Silva P, Massano Cardoso S, Ferreira AM; Portuguese DYSIS Study Investigators.

Prim Care Diabetes. 2015 Aug;9(4):283-9. doi: 10.1016/j.pcd.2014.09.002. Epub 2014 Nov 4.

PMID:
25449144
20.

What is the most effective strategy for managing diabetic dyslipidaemia?

Reasner CA.

Atheroscler Suppl. 2005 Sep;6(3):21-7. Review.

PMID:
16054442

Supplemental Content

Support Center